Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 May 25;186(11):2283-2285.
doi: 10.1016/j.cell.2023.04.034.

A budding new approach strengthens an important message

Seth J Zost  1 , Robert H Carnahan  2
Affiliations
Comment

A budding new approach strengthens an important message

Seth J Zost et al. Cell. .

Abstract

In vaccinology, both mRNA-based delivery of genes encoding antigens as well as nanoparticle-based vaccines have shown great promise in tackling challenging pathogens. In this issue of Cell, Hoffmann et al. combine these two approaches, harnessing the same cellular pathway hijacked by many viruses to boost immune responses to SARS-CoV-2 vaccination.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests S.J.Z. and R.H.C. are co-inventors on patent applications filed by Vanderbilt University relating to SARS-CoV-2 monoclonal antibodies.

Figures

Figure 1
Figure 1
ESCRT-mediated production of eVLPs leads to enhanced immune responses following SARS-CoV-2 mRNA immunization mRNA-mediated delivery of membrane-bound SARS-CoV-2 S protein allows surface expression (top), while mRNA delivery of EABR-modified S protein (bottom) leads to an enhanced immune response through both surface expression and release of eVLPs decorated with S.
See this image and copyright information in PMC

Comment on

References

    1. Gilbert P.B., Montefiori D.C., McDermott A.B., Fong Y., Benkeser D., Deng W., Zhou H., Houchens C.R., Martins K., Jayashankar L., et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2022;375:43–50. doi: 10.1126/science.abm3425. - DOI - PMC - PubMed
    1. Corbett K.S., Edwards D.K., Leist S.R., Abiona O.M., Boyoglu-Barnum S., Gillespie R.A., Himansu S., Schafer A., Ziwawo C.T., DiPiazza A.T., et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020;586:567–571. doi: 10.1038/s41586-020-2622-0. - DOI - PMC - PubMed
    1. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S., Tang G.W.K., Ferris D.G., Steben M., Bryan J., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N. Engl. J. Med. 2007;356:1928–1943. doi: 10.1056/NEJMoa061760. - DOI - PubMed
    1. Nguyen B., Tolia N.H. Protein-based antigen presentation platforms for nanoparticle vaccines. NPJ Vaccines. 2021;6:70. doi: 10.1038/s41541-021-00330-7. - DOI - PMC - PubMed
    1. Keech C., Albert G., Cho I., Robertson A., Reed P., Neal S., Plested J.S., Zhu M., Cloney-Clark S., Zhou H., et al. Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. N. Engl. J. Med. 2020;383:2320–2332. doi: 10.1056/NEJMoa2026920. - DOI - PMC - PubMed